Esophageal Motility Disorders Market

 Market Overview:

The 7 major esophageal motility disorders markets are expected to exhibit a CAGR of 5.93% during 2024-2034.

The esophageal motility disorders market has been comprehensively analyzed in IMARC's new report titled "Esophageal Motility Disorders Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Esophageal motility disorders (EMDs) encompass a group of medical conditions characterized by abnormal muscle contractions within the esophagus, the narrow passage extending from the mouth to the stomach. These diseases disrupt the coordinated movement of liquids and food from the mouth to the abdomen, leading to a range of symptoms. Common indications of EMDs include dysphagia (difficulty swallowing), chest pain, regurgitation, heartburn, and a sensation of food getting stuck in the throat. These symptoms can substantially impact a patient's quality of life and nutritional intake. The diagnosis of EMDs involves a combination of clinical evaluation, esophageal function tests, and imaging studies. High-resolution manometry is a crucial diagnostic tool that measures pressure changes within the esophageal muscles during swallowing. Additionally, the healthcare provider might recommend imaging techniques like barium swallow studies and esophageal endoscopy to assess structural abnormalities and rule out various other potential causes of underlying symptoms.

The increasing incidences of achalasia, resulting from an autoimmune response that affects the nerves controlling the esophagus, are primarily driving the esophageal motility disorders market. In addition to this, the inflating utilization of minimally invasive procedures, such as endoscopic treatments and peroral endoscopic myotomies (POEM), aimed at rectifying dysfunctional esophageal contractions and restoring normal passage, is also creating a positive outlook for the market. These surgical interventions offer better outcomes with fewer complications, making them increasingly popular among both patients and physicians. Moreover, the widespread adoption of dietary adjustments, coupled with behavioral therapies, for ameliorating EMDs by optimizing swallowing techniques and bolstering muscle coordination is further propelling the market growth. Apart from this, the rising usage of pharmacological interventions like calcium channel blockers, nitrates, and anticholinergic medications to manage symptoms and improve function is acting as another significant growth-inducing factor. Additionally, the growing research in the field of neurogastroenterology to launch targeted therapies that aim to modulate the nervous system's control of esophageal function is also augmenting the market growth. Furthermore, the escalating application of regenerative medicine approaches, encompassing stem cell therapy and tissue engineering strategies, which hold the potential to rejuvenate and restore proper esophageal muscle function in individuals suffering from the illness, is expected to drive the esophageal motility disorders market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the esophageal motility disorders market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for esophageal motility disorders and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the esophageal motility disorders market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the esophageal motility disorders market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the esophageal motility disorders market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current esophageal motility disorders marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the esophageal motility disorders market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the esophageal motility disorders market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the esophageal motility disorders market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of esophageal motility disorders across the seven major markets?
• What is the number of prevalent cases (2018-2034) of esophageal motility disorders by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of esophageal motility disorders by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of esophageal motility disorders by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with esophageal motility disorders across the seven major markets?
• What is the size of the esophageal motility disorders patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of esophageal motility disorders?
• What will be the growth rate of patients across the seven major markets?
   

Esophageal Motility Disorders: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for esophageal motility disorders drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the esophageal motility disorders market?
• What are the key regulatory events related to the esophageal motility disorders market?
• What is the structure of clinical trial landscape by status related to the esophageal motility disorders market?
• What is the structure of clinical trial landscape by phase related to the esophageal motility disorders market?
• What is the structure of clinical trial landscape by route of administration related to the esophageal motility disorders market?